David Malkin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/360305/publications.pdf

Version: 2024-02-01

180 papers	13,066 citations	34076 52 h-index	25770 108 g-index
189 all docs	189 docs citations	189 times ranked	17570 citing authors

#	Article	IF	Citations
1	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	13.7	761
2	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 2012, 148, 59-71.	13.5	743
3	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	0.8	692
4	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	13.5	596
5	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	18.1	376
6	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncology, The, 2016, 17, 1295-1305.	5.1	373
7	Li-Fraumeni Syndrome. Genes and Cancer, 2011, 2, 475-484.	0.6	364
8	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	3.2	358
9	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncology, The, 2011, 12, 559-567.	5.1	345
10	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	2.8	318
11	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nature Genetics, 2015, 47, 257-262.	9.4	306
12	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature, 2019, 572, 67-73.	13.7	293
13	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268
14	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	13.7	266
15	DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies. Clinical Cancer Research, 2018, 24, 2251-2261.	3.2	260
16	BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	0.8	244
17	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. Cancer Cell, 2014, 26, 33-47.	7.7	241
18	Excessive genomic DNA copy number variation in the Liâ€“Fraumeni cancer predisposition syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11264-11269.	3.3	192

#	Article	IF	Citations
19	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	7.7	191
20	TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors. Journal of Clinical Oncology, 2010, 28, 1995-2001.	0.8	189
21	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. European Journal of Cancer, 2014, 50, 987-996.	1.3	180
22	Impact of Craniospinal Dose, Boost Volume, and Neurologic Complications on Intellectual Outcome in Patients With Medulloblastoma. Journal of Clinical Oncology, 2014, 32, 1760-1768.	0.8	177
23	Prevalence and Functional Consequence of TP53 Mutations in Pediatric Adrenocortical Carcinoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 602-609.	0.8	164
24	InheritedTP53Mutations and the Liâ€“Fraumeni Syndrome. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026187.	2.9	161
25	Signatures of copy number alterations in human cancer. Nature, 2022, 606, 984-991.	13.7	154
26	Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma. Cancer Research, 2010, 70, 160-171.	0.4	152
27	Universal Poor Survival in Children With Medulloblastoma Harboring Somatic TP53 Mutations. Journal of Clinical Oncology, 2010, 28, 1345-1350.	0.8	148
28	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	3.4	148
29	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	3.9	146
30	Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathologica, 2014, 128, 583-595.	3.9	137
31	Younger Age of Cancer Initiation Is Associated with Shorter Telomere Length in Li-Fraumeni Syndrome. Cancer Research, 2007, 67, 1415-1418.	0.4	134
32	Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr. Clinical Cancer Research, 2017, 23, e1-e5.	3.2	130
33	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	13.7	129
34	Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science, 2018, 361, .	6.0	121
35	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	9.4	112
36	Clinical and treatment factors determining longâ€term outcomes for adult survivors of childhood lowâ€grade glioma: A populationâ€based study. Cancer, 2016, 122, 1261-1269.	2.0	109

#	Article	IF	Citations
37	Hereditary cancer predisposition in children: Genetic basis and clinical implications. International Journal of Cancer, 2006, 119, 2001-2006.	2.3	102
38	Tumour predisposition and cancer syndromes as models to study geneâ€“environment interactions. Nature Reviews Cancer, 2020, 20, 533-549.	12.8	93
39	Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. European Journal of Cancer, 2015, 51, 977-983.	1.3	87
40	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, 3644.	5.8	86
41	Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer, 2019, 125, 3514-3525.	2.0	86
42	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
43	Attitudes of parents toward the return of targeted and incidental genomic research findings in children. Genetics in Medicine, 2014, 16, 633-640.	1.1	82
44	Routine TP53 testing for breast cancer under age 30: ready for prime time?. Familial Cancer, 2012, 11, 607-613.	0.9	74
45	Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes. Cancer Cell, 2015, 27, 712-727.	7.7	74
46	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. Journal of Clinical Oncology, 2016, 34, 4161-4170.	0.8	72
47	Germline p53 Mutations and Heritable Cancer. Annual Review of Genetics, 1994, 28, 443-465.	3.2	70
48	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.4	68
49	Tissue-specific expression of SV40 in tumors associated with the Liâ€“Fraumeni syndrome. Oncogene, 2001, 20, 4441-4449.	2.6	64
50	High frequency of mismatch repair deficiency among pediatric high grade gliomas in <scp>J</scp>ordan. International Journal of Cancer, 2016, 138, 380-385.	2.3	62
51	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. Oncotarget, 2016, 7, 28169-28182.	0.8	62
52	Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma. Cell Stem Cell, 2018, 22, 414-427.e6.	5.2	61
53	Imaging of Cancer Predisposition Syndromes in Children. Radiographics, 2011, 31, 263-280.	1.4	59
54	p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis. Cell Cycle, 2016, 15, 3210-3219.	1.3	56

#	Article	IF	Citations
55	Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 2021, 7, 1800.	3.4	55
56	The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Reports, 2017, 19, 2304-2318.	2.9	53
57	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	15.2	53
58	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death and Differentiation, 2022, 29, 1071-1073.	5.0	53
59	Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nature Communications, 2020, 11, 3945.	5.8	52
60	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Experimental Hematology, 2003, 31, 693-701.	0.2	50
61	Optimized knock-in of point mutations in zebrafish using CRISPR/Cas9. Nucleic Acids Research, 2018, 46, e102-e102.	6.5	50
62	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	5.8	47
63	Ovarian embryonal rhabdomyosarcoma is a rare manifestation of the DICER1 syndrome. Human Pathology, 2015, 46, 917-922.	1.1	46
64	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discovery, 2021, 11, 1176-1191.	7.7	46
65	Comparison of survival outcomes in patients with intracranial germinomas treated with radiation alone versus reduced-dose radiation and chemotherapy. Child's Nervous System, 1998, 14, 596-601.	0.6	45
66	The role of p53 in human cancer. , 2001, 51, 231-243.		45
67	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	2.3	42
68	Predisposition to Pediatric and Hematologic Cancers: A Moving Target. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e44-e55.	1.8	41
69	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	0.8	40
70	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal of Clinical Oncology, 2021, 39, 2463-2473.	0.8	38
71	A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome. Cancer Genetics, 2015, 208, 47-51.	0.2	36
72	Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. Journal of Pathology, 2019, 249, 319-331.	2.1	36

#	Article	IF	Citations
73	Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: Randomized placebo-controlled study in childhood acute lymphoblastic leukemia. American Journal of Hematology, 1994, 47, 27-32.	2.0	34
74	Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatric Blood and Cancer, 2006, 47, 773-784.	0.8	34
75	Expression of Insulin-Like Growth Factor Pathway Proteins in Rhabdomyosarcoma: IGF-2 Expression is Associated with Translocation-Negative Tumors. Pediatric and Developmental Pathology, 2009, 12, 127-135.	0.5	34
76	Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors. Journal of Neuro-Oncology, 2014, 118, 225-238.	1.4	34
77	p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome. Oncogene, 1999, 18, 3970-3978.	2.6	33
78	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility. Journal of Clinical Oncology, 2016, 34, 3697-3704.	0.8	33
79	Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium. American Journal of Gastroenterology, 2016, 111, 275-284.	0.2	33
80	DICER1 syndrome: Approach to testing and management at a large pediatric tertiary care center. Pediatric Blood and Cancer, 2018, 65, e26720.	0.8	33
81	The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. Pediatric Blood and Cancer, 2017, 64, e26441.	0.8	30
82	The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass. Clinical Cancer Research, 2017, 23, e133-e137.	3.2	29
83	The CXCR4-SDF1Î± axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clinical and Experimental Metastasis, 2008, 25, 1-10.	1.7	28
84	Pediatric imaging in DICER1 syndrome. Pediatric Radiology, 2017, 47, 1292-1301.	1.1	28
85	Management of familial cancer: sequencing, surveillance and society. Nature Reviews Clinical Oncology, 2014, 11, 723-731.	12.5	27
86	Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precision Oncology, 2021, 5, 75-87.	1.5	27
87	Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Medicine, 2015, 4, 781-790.	1.3	25
88	Somatic DICER1 mutations in adult-onset pulmonary blastoma. European Respiratory Journal, 2016, 47, 1879-1882.	3.1	22
89	An eHealth decisionâ€support tool to prioritize referral practices for genetic evaluation of patients with Wilms tumor. International Journal of Cancer, 2020, 146, 1010-1017.	2.3	22
90	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncology, 2021, 7, 1806.	3.4	22

#	Article	IF	Citations
91	The Estrogen Receptor Pathway in Rhabdomyosarcoma: A Role for Estrogen Receptor-Î² in Proliferation and Response to the Antiestrogen 4â€²OH-Tamoxifen. Cancer Research, 2008, 68, 3476-3485.	0.4	21
92	Retrospective evaluation of a decisionâ€support algorithm (MIPOGG) for genetic referrals for children with neuroblastic tumors. Pediatric Blood and Cancer, 2018, 65, e27390.	0.8	21
93	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clinical Epigenetics, 2019, 11, 117.	1.8	21
94	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. Journal of Neuro-Oncology, 2019, 142, 39-48.	1.4	21
95	Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. , 2000, 34, 242-249.		20
96	Syndromes Predisposing to Pediatric Central Nervous System Tumors: Lessons Learned and New Promises. Current Neurology and Neuroscience Reports, 2012, 12, 153-164.	2.0	20
97	Costâ€effectiveness of early cancer surveillance for patients with Liâ€“Fraumeni syndrome. Pediatric Blood and Cancer, 2019, 66, e27629.	0.8	20
98	â€œBalancing Expectations with Actual Realitiesâ€: Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. Journal of Personalized Medicine, 2020, 10, 9.	1.1	20
99	Genotype Versus Phenotype: The Yin and Yang of Germline TP53 Mutations in Li-Fraumeni Syndrome. Journal of Clinical Oncology, 2015, 33, 2331-2333.	0.8	19
100	Mutations in the RAS/MAPK Pathway Drive Replication Repairâ€“Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discovery, 2021, 11, 1454-1467.	7.7	19
101	Absence of germline and somatic p53 alterations in children with sporadic brain tumors. Journal of Neuro-Oncology, 2001, 52, 227-235.	1.4	18
102	Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle, 2009, 8, 4060-4066.	1.3	17
103	Comprehensive characterization of a Canadian cohort of von Hippelâ€Lindau disease patients. Clinical Genetics, 2019, 96, 461-467.	1.0	16
104	Simian virus 40 and non-Hodgkin lymphoma. Lancet, The, 2002, 359, 812-813.	6.3	15
105	Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome. Journal of the National Cancer Institute, 2018, 110, 1418-1421.	3.0	15
106	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. Cancer Research, 2019, 79, 2208-2219.	0.4	15
107	Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma. Cancer Research, 2021, 81, 5625-5637.	0.4	15
108	Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas. Child's Nervous System, 1998, 14, 590-595.	0.6	14

#	Article	IF	Citations
109	The cancer predisposition revolution. Science, 2016, 352, 1052-1053.	6.0	14
110	Evidence for genetic anticipation in vonHippel-Lindau syndrome. Journal of Medical Genetics, 2018, 55, 395-402.	1.5	14
111	â€œA change in perspectiveâ€• Exploring the experiences of adolescents with hereditary tumor predisposition. Pediatric Blood and Cancer, 2019, 66, e27445.	0.8	13
112	Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Childrenâ€™s Oncology Group ARAR0332 protocol.. Journal of Clinical Oncology, 2016, 34, 10515-10515.	0.8	12
113	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Medicine, 2020, 9, 447-459.	1.3	11
114	TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. Cancers, 2020, 12, 2049.	1.7	11
115	Epstein-Barr virus-associated lymphoproliferative disorder in a child undergoing therapy for localized rhabdomyosarcoma. , 2000, 34, 358-360.		10
116	Predictive Genetic Testing for Childhood Cancer: Taking the Road Less Traveled By. Journal of Pediatric Hematology/Oncology, 2004, 26, 546-548.	0.3	10
117	Nearly Half of TP53 Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Childrenâ€™s Oncology Group. JCO Precision Oncology, 2020, 4, 1187-1195.	1.5	10
118	Family historyâ€taking practices and genetic confidence in primary and tertiary care providers for childhood cancer survivors. Pediatric Blood and Cancer, 2018, 65, e26923.	0.8	9
119	Tumor surveillance for children and adolescents with cancer predisposition syndromes: The psychosocial impact reported by adolescents and caregivers. Pediatric Blood and Cancer, 2021, 68, e29021.	0.8	9
120	Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network. Oncotarget, 2016, 7, 49611-49622.	0.8	9
121	Li-Fraumeni Syndrome and p53 in 2015: Celebrating their Silver Anniversary. Clinical and Investigative Medicine, 2016, 39, 37.	0.3	9
122	DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategiesâ€”Response. Clinical Cancer Research, 2019, 25, 1689-1690.	3.2	8
123	Parentsâ€™, Health Care Professionalsâ€™, and Scientistsâ€™ Experiences of a Precision Medicine Pilot Trial for Patients With High-Risk Childhood Cancer: A Qualitative Study. JCO Precision Oncology, 2019, 3, 1-11.	1.5	8
124	Second rhabdoid tumor 8 years after treatment of atypical teratoid/rhabdoid tumor in a child with germline SMARCB1 mutation. Pediatric Blood and Cancer, 2019, 66, e27546.	0.8	8
125	A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. British Journal of Cancer, 2020, 122, 1231-1241.	2.9	8
126	Metachronous Neuroblastoma in an Infant With Germline Translocation Resulting in Partial Trisomy 2p. Journal of Pediatric Hematology/Oncology, 2014, 36, e193-e196.	0.3	7

#	Article	IF	Citations
127	Super-TransactivationTP53Variant in the Germline of a Family with Li-Fraumeni Syndrome. Human Mutation, 2016, 37, 889-892.	1.1	7
128	Cancer surveillance for individuals with Li-Fraumeni syndrome. European Journal of Human Genetics, 2020, 28, 1481-1482.	1.4	7
129	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	1.1	7
130	Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status. Journal of Pediatric Hematology/Oncology, 2021, 43, e635-e641.	0.3	7
131	Assessment ofTP53Polymorphisms andMDM2SNP309 in Premenopausal Breast Cancer Risk. Human Mutation, 2017, 38, 265-268.	1.1	6
132	Underlying undiagnosed inherited marrow failure syndromes among children with cancer. Pediatric Blood and Cancer, 2017, 64, 302-305.	0.8	6
133	Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes. Pediatric Blood and Cancer, 2020, 67, e28758.	0.8	6
134	Precision Child Health: an Emerging Paradigm for Paediatric Quality and Safety. Current Treatment Options in Pediatrics, 2020, 6, 317-324.	0.2	6
135	Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors. Journal of Clinical Oncology, 2021, 39, JCO.21.00018.	0.8	6
136	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. Journal of Neuro-Oncology, 2021, 155, 63-70.	1.4	6
137	Gliomas in the context of Li-Fraumeni syndrome: An international cohort.. Journal of Clinical Oncology, 2019, 37, 1517-1517.	0.8	6
138	Perspectives and Experiences of Parents and Adolescents Who Participate in a Pediatric Precision Oncology Program: "When You Feel Helpless, This Kind of Thing Is Very Helpful". JCO Precision Oncology, 2022, 6, e2100444.	1.5	6
139	Low prevalence of complications in severe neutropenic children with cancer in the unprotected environment of an overnight camp. Pediatric Blood and Cancer, 2007, 48, 148-151.	0.8	5
140	Pediatric oncology clinical trial participation where the geography is vast: Development of a clinical research system for tertiary and satellite centers in Ontario, Canada. Pediatric Blood and Cancer, 2018, 65, e26901.	0.8	5
141	TERT promotor variant associated with poor clinical outcome in a patient with novel RBM15â€MKL1 fusionâ€positive pediatric acute megakaryoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28542.	0.8	5
142	Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer. Familial Cancer, 2021, 20, 289-291.	0.9	5
143	The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. Cell Cycle, 2010, 9, 1951-1959.	1.3	4
144	Surveillance for children at genetic risk for cancer: Are we ready?. Pediatric Blood and Cancer, 2014, 61, 1337-1338.	0.8	4

#	Article	IF	Citations
145	Biochemical and imaging surveillance in Li-Fraumeni syndrome â€“ Authorsâ€™ reply. Lancet Oncology, The, 2016, 17, e473.	5.1	4
146	Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. Pediatric Blood and Cancer, 2017, 64, e26340.	0.8	4
147	Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma. Cancer, 2018, 124, 1242-1250.	2.0	3
148	Report of a bi-allelic truncating germline mutation in TP53. Familial Cancer, 2019, 18, 101-104.	0.9	3
149	Diagnostic accuracy of imaging approaches for early tumor detection in children with Li-Fraumeni syndrome. Pediatric Radiology, 2022, 52, 1283-1295.	1.1	3
150	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e347-e347.	0.8	2
151	Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation. JCO Precision Oncology, 2021, 5, 1339-1347.	1.5	2
152	Evaluation of rapid whole-body magnetic resonance as screening strategy for early cancer detection in 57 Brazilian Li-Fraumeni syndrome patients.. Journal of Clinical Oncology, 2015, 33, 1534-1534.	0.8	2
153	Regulation of cellular proliferation effects on alteration of normal signaling pathways. Medical and Pediatric Oncology, 1996, 27, 20-24.	1.0	1
154	Translational Childhood Cancer Genomics. JAMA Oncology, 2016, 2, 384.	3.4	1
155	Liâ€“Fraumeni Syndrome â˜†. , 2018, , .		1
156	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. Patient Preference and Adherence, 2018, Volume 12, 2103-2110.	0.8	1
157	Management of orbital rhabdomyosarcoma in a child with Li-Fraumeni syndrome. Journal of AAPOS, 2019, 23, 182-185.	0.2	1
158	Abstract 2114: Horvath clock as a predictor of cancer risk in LFS patients. , 2021, , .		1
159	Childhood head trauma and the risk of childhood brain tumours: A caseâ€control study in Ontario, Canada. International Journal of Cancer, 2022, 150, 795-801.	2.3	1
160	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	0.6	1
161	Abstract 5224: The PRecision Oncology For Young peopLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. Cancer Research, 2022, 82, 5224-5224.	0.4	1
162	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. Neuro-Oncology, 2016, 18, iii94.1-iii94.	0.6	0

#	Article	IF	Citations
163	PNR-08NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS. Neuro-Oncology, 2016, 18, iii8.2-iii8.	0.6	0
164	ATRT-13. CANCER PREDISPOSITION AMONG CHILDREN WITH RHABDOID TUMORS: A SINGLE-CENTRE RETROSPECTIVE REVIEW. Neuro-Oncology, 2018, 20, i30-i30.	0.6	0
165	Aggressive embryonal rhabdomyosarcoma in a 3-month-old boy: A clinical and molecular analysis. Pediatric Hematology and Oncology, 2018, 35, 407-414.	0.3	0
166	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. Neuro-Oncology, 2018, 20, i92-i92.	0.6	0
167	Nonâ€rhabdomyosarcoma soft tissue sarcomas diagnosed in patients at a young age. An overview of clinical, pathological, and molecular findings. Pediatric Blood and Cancer, 2021, 68, e29022.	0.8	0
168	Abstract 2591: Characterizing the metabolic landscape of dermal fibroblasts in Li-Fraumeni Syndrome for the prediction of cancer risk and drug response. , 2021, , .		0
169	Abstract 886: Prediction of outcome in Li-Fraumeni Syndrome: Development of an integrative function-based prognostic model. , 2021, , .		0
170	Abstract 2689: Investigating the molecular mechanisms linking disrupted growth homeostasis to tumourigenesis in Li-Fraumeni Syndrome. , 2021, , .		0
171	Li-Fraumeni Syndrome. , 2021, , 1-21.		0
172	Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants. Blood, 2012, 120, 2069-2069.	0.6	0
173	Attitudes to the return of incidental and targeted genomic findings obtained in a high-risk pediatric cancer versus an inherited genetic condition research setting.. Journal of Clinical Oncology, 2013, 31, 10066-10066.	0.8	0
174	Biochemical and imaging surveillance for Li-Fraumeni syndrome: The â€œToronto Protocolâ€•at 11 years.. Journal of Clinical Oncology, 2015, 33, e12546-e12546.	0.8	0
175	Abstract P136: Response to alpelisib in an adolescent with PIK3CA-mutated metastatic gastrointestinal stromal tumour. , 2021, , .		0
176	IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors. Neuro-Oncology, 2022, 24, i81-i81.	0.6	0
177	Abstract 844: Germline TP53 missense mutations at codon338 confer adult-onset cancer risk through weakened p53 protein oligomeric stability that impairs its tumor suppressive mechanisms. Cancer Research, 2022, 82, 844-844.	0.4	0
178	Abstract 3047: Investigating the interaction between the microbiome and mutant p53 in Li-Fraumeni Syndrome. Cancer Research, 2022, 82, 3047-3047.	0.4	0
179	Abstract 849: Characterization and prevention of radiation-induced malignancies in Li-Fraumeni Syndrome. Cancer Research, 2022, 82, 849-849.	0.4	0
180	Abstract 1428: DNA methylation predicts early onset of primary tumor in patients with Li-Fraumeni syndrome. Cancer Research, 2022, 82, 1428-1428.	0.4	0